Loading...
A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer.
Hickish, T Cassidy, J Propper, D Chau, I Falk, S Ford, H Iveson, T Braun, Michael S Potter, V Macpherson, I
Hickish, T
Cassidy, J
Propper, D
Chau, I
Falk, S
Ford, H
Iveson, T
Braun, Michael S
Potter, V
Macpherson, I
Citations
Altmetric:
Abstract
This randomised phase II trial aimed to compare efficacy of the irreversible ErbB family blocker, afatinib, with cetuximab in patients with KRAS wild-type metastatic colorectal adenocarcinoma (mCRC) with progression following oxaliplatin- and irinotecan-based regimens. Efficacy in patients with KRAS mutations was also evaluated.
Description
Date
2014-12
Publisher
Collections
Keywords
Type
Article
Citation
A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer. 2014, 50 (18):3136-44 Eur J Cancer